Introduction
Methods
Study setting and study population
Assessments and measurements
Statistical analysis
Ethical consideration
Results
General characteristics of study participants
Variables | HAART group (n=113) | pre-HAART group (n=113) |
---|---|---|
Gender = Female, n (%) | 75 (66.4) | 72 (63.7) |
Male, n (%) | 38 (33.6) | 41 (36.3) |
Age, (years), mean ± SD | 37.2 ( 8.7) | 33.7 (8.3)** |
18–30 years, n (%) | 26 (23) | 49 (43.4) |
31–40 years, n (%) | 59 (52.2) | 47(41.6) |
41–50 years, n (%) | 21 (18.6) | 12 (10.6) |
>50 years, n (%) | 7 (6.2) | 5 (4.4) |
BMI (Kg/m2), mean ± SD | 22.3 (4.1) | 21.5 ( 3.9) |
<18 Kg/m2, n (%) | 8 (7) | 14 (12.4) |
18–25 Kg/m2, n (%) | 82 (72.6) | 84 (74.3) |
>25 Kg/m2, n (%) | 23 (20.4) | 15 (13.3) |
CD4+ count (cells/mm3), mean ± SD | 460 (221) | 356 (216.7) *** |
< 200 cells/mm3, n (%) | 16 (14.2) | 29 (25.7) |
200–400 cells/mm3, n (%) | 32 (28.3) | 44 (38.9) |
> 400 cells/mm3, n (%) | 65 (57.5) | 40 (35.4) |
Duration of HAART, mean ±SD | 49.4 (16.5) | -- |
12–24 months, n (%) | 10 (8.8) | -- |
24–36 months, n (%) | 18 (15.9) | -- |
36–48 months, n (%) | 27 (23.9) | -- |
48–60 months, n (%) | 24 (21.2) | -- |
> 60 years, n (%) | 34 (30.1) | -- |
Current anti-TB users, n (%) | 0 | 4 (3.5) |
Current smoking, n (%) | 6 (5.3) | 7 (6.2) |
Past smoking, n (%) | 15 (13.3) | 13 (11.5) |
Dyslipidemia and characteristics of lipid profiles
Parameters | HAART group (n=113) | Pre-HAART group (n=113) |
---|---|---|
Total cholesterol, mean ± SD | 199.6 (51.5) | 155.4 (44) *** |
< 200mg/dl | 64 (56.6%) | 95 (84.1%) |
≥ 200mg/dl | 49 (43.4%) | 18 (15.9%) *** |
HDL-cholesterol, mean ± SD | 43.2 (14.3) | 33.3 (12.8 ) *** |
< 40mg/dl | 49 (43.4%) | 72 (63.7%) ** |
≥ 40mg/dl | 64 (56.6%) | 41 (36.3%) |
LDL-cholesterol, mean ± SD | 119.3 (43) | 97.3 (36.2) *** |
< 130mg/dl | 75 (66.4%) | 96 (85%) |
≥ 130mg/dl | 38 (33.6%) | 17 (15.0%) ** |
Triglycerides, mean ± SD | 204 (143) | 138 (76 ) *** |
< 150mg/dl | 50 (44.2%) | 78 (69%) |
≥150mg/dl | 63 (55.8%) | 35 (31.0%) *** |
TC/HDL-c ratio, mean ± SD | 5.2 (2.4) | 5.3 (2.6) |
< 5 | 62 (54.9%) | 64 (56.6%) |
≥ 5 | 51 (45.1%) | 49 (43.4%) |
Dyslipidemia and first-line HAART
Lipid profile | ZDV-based n=58 (%) | d4T-based n=55 (%) |
p-value
|
---|---|---|---|
TC ≥ 200 mg/dl | 25 (43.1) | 24 (43.6) | 0.95 |
HDL-c < 40 mg/dl | 24 (41.4) | 25 (45.4) | 0.66 |
LDL-c ≥ 130 mg/dl | 20 (34.5) | 18 (32.7) | 0.84 |
TG ≥ 150 mg/dl | 32 (55.2) | 31 (56.4) | 0.41 |
TC/HDL-c ratio ≥5 | 24 (41.4) | 27 (49.1) | 0.89 |
Lipid profile | EFV-based n=46 (%) | NVP-based n=67 (%) | P value |
---|---|---|---|
TC > 200 mg/dl | 18 (39.1) | 31 (46.3) | 0.45 |
HDL-c < 40 mg/dl | 22 (47.8) | 27 (40.3) | 0.43 |
LDL-c > 130 mg/dl | 14 (30.4) | 24 (35.8) | 0.55 |
TG > 150 mg/dl | 25 (54.3) | 38 (56.7) | 0.80 |
TC/HDL ratio > 5 | 22 (47.8) | 29 (43.3) | 0.63 |
Dyslipidemia and risk factors
Explanatory variable | Outcome | variables | ||
---|---|---|---|---|
TC ≥ 200 mg/dl | HDL< 40 mg/dl | LDL ≥ 130 mg/dl | TG ≥ 150 mg/dl | |
AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | AOR (95% CI) | |
CD4+cells ≥200/mm3* | 1.00 | 1.00 | 1.00 | 1.00 |
CD4+cells < 200/mm3 | 0.91 (0.39-2.10) | 1.95 (0.94-4.07) | 0.89 (0.37-2.15) | 0.87 (0.42-1.80) |
P-value | 0.82 | 0.07 | 0.79 | 0.71 |
BMI ≤ 25 Kg/m2* | 1.00 | 1.00 | 1.00 | 1.00 |
BMI > 25 Kg/m2 | 2.96 (1.35-6.49) | 0.55 (0.26-1.18) | 2.66 (1.17-5.59) | 2.82 (1.31-6.07) |
P-value |
0.007
| 0.13 |
0.02
|
0.008
|
Gender = Female* | 1.00 | 1.00 | 1.00 | 1.00 |
Male | 0.71 (0.32-1.57) | 0.73 (0.38-1.42) | 0.53 (0.22-1.25) | 1.44 (0.74-2.82) |
P-value | 0.4 | 0.36 | 0.15 | 0.28 |
Age ≤ 40 years* | 1.00 | 1.00 | 1.00 | 1.00 |
Age > 40 years | 3.04 (1.41-6.55) | 2.64 (1.23-5.69) | 3.28 (1.48-7.30) | 1.47 (0.71-3.05) |
P-value |
0.004
|
0.01
|
0.004
| 0.29 |
Pre-HAART* | 1.00 | 1.00 | 1.00 | 1.00 |
HAART | 3.80 (1.34-7.44) | 0.44 (0.25-0.78) | 2.64 (1.31-5.32) | 2.50 (1.41-4.42) |
P-value |
<0.0001
|
0.005
|
0.006
|
0.002
|
No smoking* | 1.00 | 1.00 | 1.00 | 1.00 |
Current smoking | 0.90 (0.20-4.00) | 2.13 (0.57-8.01) | 0.32 (0.36-2.82) | 0.75 (0.21-2.64) |
P-value | 0.89 | 0.26 | 0.3 | 0.65 |
No smoking* | 1.00 | 1.00 | 1.00 | 1.00 |
Past smoking | 0.77 (0.25-2.33) | 1.46 (0.57-3.75) | 0.56 (0.16-1.91) | 0.67 (0.26-1.75) |
P-value | 0.64 | 0.43 | 0.35 | 0.42 |
No ant-TB drug * | 1.00 | 1.00 | 1.00 | 1.00 |
Ant-TB drug | 1.85(0.17-20.51) | NA | 1.74(0.1519.82) | NA |
P-value | 0.62 | NA | 0.65 | NA |
Explanatory variables | Outcome | variables | ||
---|---|---|---|---|
TC ≥ 200 mg/dl | HDL-c < 40 mg/dl | LDL-c ≥ 130mg/dl | TG ≥150 mg/dl | |
BMI > 25kg/m2 | ||||
UOR (95% CI) | 3.09 (1.18-8.05)* | 0.50 (0.19-1.33) | 2.68 (1.05-6.85)* | 2.71 (0.98-7.50) |
AOR (95% CI) | 3.21 (1.16-8.91)* | 0.49 (0.17-1.39) | 2.44 (0.91-6.51) | 2.92 (0.99-8.44) |
Gender (male) | ||||
UOR (95% CI) | 0.93 (0.42-2.04) | 1.28 (0.58-2.80) | 0.49 (0.20-1.19) | 1.14 (0.52-2.51) |
AOR (95% CI) | 0.68 (0.23-2.04) | 0.69 (0.24-1.96) | 0.43 (0.13-1.46) | 1.09 (0.40-2.99) |
Age > 40 years | ||||
UOR (95% CI) | 3.13 (1.28-7.63)* | 3.14 (1.29-7.64)* | 2.08 (0.86-5.00) | 1.97 (0.80-4.84) |
AOR (95% CI) | 4.43 (1.54-12.72)** | 4.22 (1.46-12.16)** | 4.28 (1.41-12.97)* | 2.12 (0.77-5.82) |
HAART ≤ 2 years | ||||
UOR (95% CI) | 0.95 (0.24-3.75) | 0.35 (0.08-1.49) | 1.85 (0.37-9.39) | 1.00 (0.26-3.97) |
AOR (95% CI) | 0.76 (0.16-3.66) | 0.30 (0.06-1.47) | 1.35 (0.22-8.20) | 0.92 (0.21-4.09) |
Current smoking | ||||
UOR (95% CI) | 0.64 (0.11-3.64) | 1.33 (0.26-6.87) | 0.38 (0.04-3.36) | 0.78 (0.15-4.06) |
AOR (95% CI) | 0.77 (0.12-5.79) | 0.70 (0.10-4.80) | 0.51 (0.04-5.82) | 0.78 (0.12-5.04) |
Past smoking | ||||
UOR (95% CI) | 1.17 (0.39-3.47) | 1.17 (0.39-3.47) | 0.45 (0.12-1.70) | 1.22 (0.40-3.70) |
AOR (95% CI) | 0.82 (0.20-3.34) | 0.62 (0.16-2.45) | 0.39 (0.08-1.98) | 0.88 (0.23-3.40) |
d4T | ||||
UOR (95% CI) | 1.02 (0.48-2.15) | 1.18 (0.56-2.49) | 0.92 (0.42-2.02 | 1.05 (0.50-2.21) |
AOR (95% CI) | 1.29 (0.57-2.93) | 1.41 (0.63-3.16) | 1.22 (0.52-2.85) | 1.17 (0.53-2.58) |
EFV | ||||
UOR(95% CI) | 0.75 (0.35-1.60) | 1.36 (0.64-2.89) | 0.78 (0.35-1.75) | 0.91 (0.43-1.93) |
AOR (95% CI) | 0.77 (0.33-1.79) | 1.36 (0.60 3.12) | 0.91 (0.37-2.22) | 0.97 (0.43-2.18) |